BioNTech (NasdaqGS:BNTX) reported a 2.49% weekly price decline following its announcement of diminished Q4 2024 earnings, where sales and net income significantly dropped compared to the previous year ...

Shares of German biotech BioNTech (Nasdaq: BNTX) dipped 2.5% to $105.86 today, after it reported financial results for the ...

BioNTech SE exceeded earnings expectations with strong oncology pipeline development, despite reduced vaccine revenue.

Advanced oncology pipeline including more than 20 active Phase 2 and Phase 3 clinical trials with a strategic focus on two priority pan-tumor ...

Five years after the start of the pandemic, the fight over who owns the underlying technologies that made the Covid-19 ...

U.S. stock futures declined on Monday after a small bout of relief on Friday as indices neared the correction zone. Futures ...

On Wall Street in the week ahead, the spotlight will be on consumer price inflation data, slated to be released on Wednesday.

The benchmark US stock measures were trending lower before Monday's opening bell as traders await fresh inflation data later in the week. Standard & Poor's 500 declined 1.1%, the Dow Jones Industrial ...

S&P 500 E-Mini futures (ESH25) are down -0.90%, andMarch Nasdaq 100 E-Mini futures (NQH25) are down -1.04% this morning, ...

BioNTech's Q4 revenue beat estimates despite lower COVID-19 vaccine sales. The company advances oncology programs, with key ...

BioNTech shares fell Monday, as the COVID-19 vaccine maker’s soft outlook offset better-than-expected quarterly results.